Brind.

AVR Reports Positive 30-Day Outcomes for DurAVR Transcatheter Heart Valve

2 reports, 1 independent Updated Sun 00:00
No new developments lately Reached 2 outlets in its first 24 hours
Reports
2
Developments
1
Repetition
50%

New informationRepeats or wire copies

AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Anteris Technologies Global Corp. announced 30-day clinical and hemodynamic outcomes for the Medium-size DurAVR® Transcatheter Heart Valve (THV) in 22 severe aortic stenosis patients. The results, presented at the Transcatheter Cardiovascular Therapeutics (TCT) Conference in San Diego, California, showed single digit mean gradients and large effective orifice areas. The study also reported no moderate or severe paravalvular leaks and no valve related mortality.

From manilatimes.net

Why it matters

Some supportBrind's analysis of the reports

The positive clinical trial results for the DurAVR THV could support market adoption of the device. The company also confirmed that it conducts clinical trials in both the US and Australia.

From manilatimes.net

Who's involved

  • AVRGlobal healthcare company developing and commercializing medical devices

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped
1 more outlet ran the same wire story